淋巴结细胞,败血症 z-bo 2020-10-17 344

　　Researchers from multiple laboratories report that the presence of immune regulatory cells in the lymph nodes may prevent a variety of sepsis, which is an uncontrolled immune response that may lead to multiple organ failure and death. Researchers have found that fibroblast reticulocytes (FRC) can be used to treat animal models of sepsis and significantly improve animal survival.

　　More than 140,000 people die of sepsis every week worldwide. The effectiveness of late treatment is very important, because patients with sepsis are usually not treated for hours or even days after the initial infection. So far, there is no cure to improve late-stage survival. So far, the design of a potential sepsis treatment for a single molecule has not been successful. This may be due to the complex interaction of multiple immune pathways. The use of cell therapy can target the activity of multiple molecules, affect multiple disease pathways, and respond to the patient's condition. Since FRC is known to regulate many immune responses in lymph nodes, researchers should study the transfer of FRC to the site of injury caused by sepsis to understand whether it can regulate immune responses. working hard now. In the first experiment, we used two mouse models. One is constructed using multiple bacterial toxins associated with sepsis, and the other is constructed using colon injury and abdominal cavity exposure. Researchers have shown that introducing FRC into the abdominal cavity can significantly improve the survival rate of mice of all ages. FRC treatment can also improve survival in a more severe intestinal injury model of sepsis. The FRC used in these experiments was cultured from animal lymph node cells, so the researchers repeated the experiment with FRC grown in unrelated mice. Improved viability (14% to 89%) indicates that cells donated by healthy people can be cultured, stored and used without the need for immune matching. Experiments also show that FRC treatment 16 hours after the injury caused by sepsis (rather than 4 hours used in other experiments) can still significantly improve survival. The experiment investigated the mechanism behind the treatment and proposed that FRC treatment can also prevent damage to the spleen (pathogens are filtered out of the blood, and various immune cells die in the spleen). The preservation of spleen function may explain the reduction of pathogen levels in the blood in the treatment of FRC in animals. Other evidence suggests that the activity of the signaling molecule nitric oxide may play an important role in the effectiveness of FRC therapy. In addition, the research team will conduct FRC treatment tests on patients.